Pfizer Inc. (NYSE:PFE) price on Friday, March 17, fall -0.67% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $40.10.
A look at the stock’s price movement, the close in the last trading session was $40.37, moving within a range at $39.985 and $40.79. The beta value (5-Year monthly) was 0.58 while the PE ratio in trailing twelve months stood at 7.33. Turning to its 52-week performance, $56.32 and $39.23 were the 52-week high and 52-week low respectively. Overall, PFE moved -7.43% over the past month.
Do You Know The Best Place To Find Gains In Volatile Markets?
In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.
Click here for full details and to join for free.
Pfizer Inc.’s market cap currently stands at around $225.73 billion, with investors looking forward to this quarter’s earnings report slated for May 01, 2023 – May 05, 2023. The company has a Forward Dividend ratio of 1.64, with its dividend yield at 4.09%. As such, investors might be keen on an upside in the stock’s price ahead of the scheduled earnings report. Analysts project the company’s earnings per share (EPS) to be $1.02, which has seen fiscal year 2023 EPS growth forecast to increase to $3.37 and about $3.79 for fiscal year 2024. Per the data, EPS growth is expected to be -48.80% for 2023 and 12.50% for the next financial year.
Analysts have a consensus estimate of $17.2 billion for the company’s revenue for the quarter, with a low and high estimate of $14.7 billion and $19 billion respectively. The average forecast suggests down to a -33.00% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue for 2023 to grow to $68.68 billion, representing a -31.50% decline on that reported in the last financial year.
Revisions could be used as tool to get short term price movement insight, and for the company that in the past seven days was no upward and no downward review(s). Turning to the stock’s technical picture we see that short term indicators suggest on average that PFE is a 100% Sell. On the other hand, the stock is on average a 100% Sell as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category.
24 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 14 analyst(s) rate the stock as a Hold, 7 recommend PFE as a Buy and 3 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Overweight which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
PFE’s current price about -2.13% and -8.14% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 34.72, while 7-day volatility ratio is 2.29% and 1.82% in the 30-day chart. Further, Pfizer Inc. (PFE) has a beta value of 0.63, and an average true range (ATR) of 0.82. Analysts have given the company’s stock an average 52-week price target of $50.63, forecast between a low of $40.00 and high of $75.00. Looking at the price targets, the low is 0.25% off current price level while to achieve the yearly target high, price needs to move -87.03%. Nonetheless, investors will most likely welcome a -19.7% jump to $48.00 which is the analysts’ median price.
In the market, a comparison of Pfizer Inc. (PFE) and its peers suggest the former has performed considerably weaker. Data shows PFE’s intraday price has changed -0.67% in last session and -24.23% over the past year. Comparatively, Johnson & Johnson (JNJ) has moved -1.07% on the day and only -12.69% in the past 12 months. Looking at another peer, we see that Eli Lilly and Company (LLY) price has dipped -0.11% on the day. However, the stock is 19.08% off its price a year ago. Moreover, Abbott Laboratories (ABT) is also down -2.04% in trading on the day while keeping a a downtrend of -18.81% over the past year. If we look at the PE ratio, we find that Pfizer Inc.’s ratio stands at 7.33 compared to Johnson & Johnson’s 22.62 and Eli Lilly and Company’s 47.64. Elsewhere, the overall performance for the S&P 500 and Dow Jones Industrial shows that the indexes are down -1.10% and -1.19% respectively in the last trading.
If we refocus on Pfizer Inc. (NYSE:PFE), historical trading data shows that trading volumes averaged 23.17 million over the past 10 days and 21.80 million over the past 3 months. The company’s latest data on shares outstanding shows there are 5.61 billion shares.
The 0.05% of Pfizer Inc.’s shares are in the hands of company insiders while institutional holders own 70.50% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 37.17 million on Jan 12, 2023, giving us a short ratio of 1.72. The data shows that as of Jan 12, 2023 short interest in Pfizer Inc. (PFE) stood at 0.66% of shares outstanding, with shares short falling to 58.02 million registered in Dec 14, 2022. Current price change has pushed the stock -21.74% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the PFE stock continues to rise going into the next quarter.